Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 393976, 4 pages
http://dx.doi.org/10.1155/2011/393976
Research Article

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults

1Infectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda
2Trinity College, Dublin 2, Ireland
3Infectious Diseases Network for Treatment and Research in Africa (INTERACT), P.O. Box 7062, Kampala, Uganda
4Uganda Heart Institute, Mulago Hospital, P.O. Box 7051, Kampala, Uganda
5St. Stephen’s AIDS Trust, London SW10 9TR, UK
6University of Liverpool, Liverpool L69 3BX, UK

Received 31 August 2010; Revised 26 November 2010; Accepted 14 February 2011

Academic Editor: Kazuo Tamura

Copyright © 2011 Pauline Byakika-Kibwika et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, “Malaria,” The Weekly Epidemiological Record, vol. 74, pp. 265–272, 1982–1997. View at Google Scholar
  2. N. French, J. Nakiyingi, E. Lugada, C. Watera, J. A. G. Whitworth, and C. F. Gilks, “Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults,” AIDS, vol. 15, no. 7, pp. 899–906, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Francesconi, M. Fabiani, M. G. Dente et al., “HIV, malaria parasites, and acute febrile episodes in ugandan adults: a case-control study,” AIDS, vol. 15, no. 18, pp. 2445–2450, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Whitworth, D. Morgan, M. Quigley et al., “Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study,” Lancet, vol. 356, no. 9235, pp. 1051–1056, 2000. View at Google Scholar · View at Scopus
  5. J. G. Kublin, P. Patnaik, C. S. Jere et al., “Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study,” Lancet, vol. 365, no. 9455, pp. 233–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Khoo, D. Back, and P. Winstanley, “The potential for interactions between antimalarial and antiretroviral drugs,” AIDS, vol. 19, no. 10, pp. 995–1005, 2005. View at Google Scholar · View at Scopus
  7. F. Nosten and N. J. White, “Artemisinin-based combination treatment of falciparum malaria,” The American Journal of Tropical Medicine and Hygiene, vol. 77, no. 6, pp. 181–192, 2007. View at Google Scholar · View at Scopus
  8. A. Yeka, G. Dorsey, M. R. Kamya et al., “Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda,” PLoS ONE, vol. 3, no. 6, Article ID e2390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Bukirwa, Y. Adoke, M. R. Kamya et al., “Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda,” Plos Clinical Trials, vol. 1, no. 1, Article ID 0010007, 2006. View at Google Scholar
  10. “FDA Issues Safety Labeling Changes for Kaletra,” FDA Issues Safety Labeling Changes for Kaletra (serial on the Internet). 2009, http://www.medscape.com.
  11. G. Lefèvre, M. Bindschedler, F. Ezzet, N. Schaeffer, I. Meyer, and M. S. Thomsen, “Pharmacokinetic interaction trial between co-artemether and mefloquine,” European Journal of Pharmaceutical Sciences, vol. 10, no. 2, pp. 141–151, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Lefèvre, S. Looareesuwan, S. Treeprasertsuk et al., “A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand,” American Journal of Tropical Medicine and Hygiene, vol. 64, no. 5-6, pp. 247–256, 2001. View at Google Scholar · View at Scopus
  13. P. German, S. Parikh, J. Lawrence et al., “Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 4, pp. 424–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Bindschedler, G. Lefèvre, P. Degen, and A. Sioufi, “Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants,” American Journal of Tropical Medicine and Hygiene, vol. 66, no. 3, pp. 293–298, 2002. View at Google Scholar · View at Scopus
  15. P. A. Matson, S. P. Luby, S. C. Redd, H. R. Rolka, and R. A. Meriwether, “Cardiac effects of standard-dose halofantrine therapy,” American Journal of Tropical Medicine and Hygiene, vol. 54, no. 3, pp. 229–231, 1996. View at Google Scholar · View at Scopus
  16. J. Karbwang, K. Na Bangchang, D. Bunnag, T. Harinasuta, and P. Laothavorn, “Cardiac effect of halofantrine,” Lancet, vol. 342, no. 8869, p. 501, 1993. View at Google Scholar · View at Scopus
  17. R. Bakshi, I. Hermeling-Fritz, I. Gathmann, and E. Alteri, “An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 94, no. 4, pp. 419–424, 2000. View at Google Scholar · View at Scopus
  18. P. German, S. Parikh, J. Lawrence et al., “Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 4, pp. 424–429, 2009. View at Publisher · View at Google Scholar · View at Scopus